Bagsværd, Denmark drugmaker created in 1989 by the merger of two Danish companies dating from the 1920s; makes obesity and diabetes medicines sold in about 170 countries and is listed on Nasdaq Copenhagen as NOVO B.
Market cap $167B on 21 Nov 2026
| Fundsmith LLP | Terry Smith | 8 | 2016–2026 |
| Bailard | 1 | 2026–2026 | |
| Giverny Capital | Francois Rochon | 1 | 2023–2023 |
| Fundsmith Equity Fund Semi-Annual Letter to Shareholders 2026 | Terry Smith explains changes to how Fundsmith Equity is run after a 2.9% fall in the first half of 2026, and exits 13 holdings including Novo Nordisk, Nike and LVMH. | Fundsmith LLP | Terry Smith | 2026 |
| Fundsmith Equity Fund Annual Letter to Shareholders 2025 | Terry Smith reports that Fundsmith Equity rose 0.8% in 2025 against 12.8% for the MSCI World Index, in its sixteenth annual letter. | Fundsmith LLP | Terry Smith | 2025 |
| Fundsmith Equity Fund Semi-Annual Letter to Shareholders 2025 | Terry Smith reports Fundsmith Equity's first-half 2025 performance against the MSCI World Index and comparators. | Fundsmith LLP | Terry Smith | 2025 |
| Fundsmith Equity Fund Annual Letter to Shareholders 2024 | Terry Smith reports Fundsmith Equity lagged the MSCI World Index's 20.8% rise in 2024 but has beaten it by 2.7% a year since inception. | Fundsmith LLP | Terry Smith | 2024 |
| Fundsmith Equity Fund Annual Letter to Shareholders 2023 | Terry Smith reports Fundsmith Equity underperformed the MSCI World Index's 16.8% rise in 2023, in its fourteenth annual letter. | Fundsmith LLP | Terry Smith | 2023 |
| Fundsmith Equity Fund Semi-Annual Letter to Shareholders 2022 | Terry Smith blames 2022's fall on inflation, rate rises and recession risk, and asks how his companies would fare in 1970s-style stagflation. | Fundsmith LLP | Terry Smith | 2022 |
| Fundsmith Equity Fund Annual Letter to Shareholders 2021 | Terry Smith reports Fundsmith Equity rose 22.1% in 2021 against 22.9% for the MSCI World, and 570.7% since its 2010 launch. | Fundsmith LLP | Terry Smith | 2021 |
| Fundsmith Equity Fund Annual Letter to Shareholders 2016 | Terry Smith reports Fundsmith Equity's 2016 results, its seventh year, against the MSCI World and UK bonds. | Fundsmith LLP | Terry Smith | 2016 |
| Giverny Capital Annual Letter to Partners 2023 | François Rochon marks 30 years of the Rochon Global Portfolio in Giverny's 2023 letter to partners. | Giverny Capital | Francois Rochon | 2023 |
| International Equity Strategy Quarterly Report, Q1 2026 | Daniel McKellar and Eric Leve report that Bailard's International Equity Strategy returned 1.32% net in Q1 2026 against the MSCI EAFE Index's -1.24%, helped by overweights in Korea and Norway and an underweight in Denmark as the closure of the Strait of Hormuz sent Brent up 94%. | Bailard | Bailard | Q1 2026 |
We exited or have started exiting: Atlas Copco, Coloplast, EssilorLuxottica, Intuit, LVMH, Magnum Ice Cream, Mettler-Toledo, Nike, Novo Nordisk, Otis, Unilever, Wolters Kluwer, and Zoetis.Show in the letter ›
Fundsmith Equity Fund Semi-Annual Letter to Shareholders 2026 · Fundsmith LLP · page 7 · 2026
Denmark lagged (-14.5%) on continued weakness from Novo Nordisk, as well as cyclical-heavy Ireland (-10.1%).Show in the letter ›
International Equity Strategy Quarterly Report, Q1 2026 · Bailard · page 4 · Q1 2026
Pharma giant Novo Nordisk continued to face competitive headwinds, leadership transitions, and disappointing drug trial results.Show in the letter ›
International Equity Strategy Quarterly Report, Q1 2026 · Bailard · page 5 · Q1 2026
Terry Smithdiscussed it in 8 letters; named it in 1 interview“Timestamps 00:38 Magnificent Seven stocks 3:52 Nvidia 6:41 AI 08:57 Consumer staples and weight-loss drugs 12:06 Novo Nordisk 17:36 What he looks for in companies 20:23 Nike 22:07 Asset allocation and share buybacks 24:48 UK companies and Asia 29:19 Financials 30:27 Judging when there’s a crisis versus a mispricing 35:09 Criticisms of the buy and sell process 39:44 Atlas Copco 41:44 Next and Autotrader Claim your first 12 weeks of Investors' Chronicle Print + Digital for just £12.” — Terry Smith on Nvidia, banks and the UK market: IC Interviews (Investors' Chronicle, 2024)
Francois Rochondiscussed it in 1 letter| Terry Smith on Nvidia, banks and the UK market: IC Interviews | Terry Smith | Investors' Chronicle | 2024-11-05 | 43 min | Returning a second time in the IC Interviews hot seat, Terry Smith is one of the biggest names in the investing world. Having set up the eponymous Fundsmith in 2010, he now manages more than £22bn of British savers’ money and has had his fair share of celebration and criticism. Funds editor Dave Baxter and Smith unpack everything from Magnificent Seven stocks and the effect of weight-loss drugs on stock markets, to consumer staples and the reason Smith doesn’t want to own market favourite, Nvidia. Also, find out what quality Smith looks for in companies and fund managers, plus why the fund’s allocation to UK stocks is so minimal. Timestamps 00:38 Magnificent Seven stocks 3:52 Nvidia 6:41 AI 08:57 Consumer staples and weight-loss drugs 12:06 Novo Nordisk 17:36 What he looks for in companies 20:23 Nike 22:07 Asset allocation and share buybacks 24:48 UK companies and Asia 29:19 Financials 30:27 Judging when there’s a crisis versus a mispricing 35:09 Criticisms of the buy and sell process 39:44 Atlas Copco 41:44 Next and Autotrader Claim your first 12 weeks of Investors' Chronicle Print + Digital for just £12. You will get instant access to our website and app, plus the magazine delivered to your door every week. To start your trial, visit www.investorschronicle.co.uk/podcasttrial *After your 12-week trial you will pay just £62 every 13 weeks by direct debit. |